Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nasus PharmaNSRX -3.96%14 EV-to-FCF is -6.08 as of Jul. 22, 2026. GuruFocus rates NSRX with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 567 Drug Manufacturers companies, Nasus Pharma ranks worse than 176366.67% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Nasus Pharma's Enterprise Value is $29.91 Mil.
Nasus Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-4.92 Mil. Therefore, Nasus Pharma's EV-to-FCF for today is -6.08.
The historical rank and industry rank for Nasus Pharma's EV-to-FCF or its related term are showing as below:
NSRX'
s EV-to-FCF Range Over the Past 10 Years
Min: -6.44 Med: 0 Max: 0
Current: -6.08
NSRX's EV-to-FCF is ranked worse than 100% of 567
companies
in the Drug Manufacturers industry
Industry Median: 21.08
vs NSRX: -6.08
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Nasus Pharma's PE Ratio (TTM) for today is calculated as:
Nasus Pharma's share price for today is $2.91.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nasus Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.649.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Nasus Pharma EV-to-FCF Related Terms
Nasus Pharma EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Nasus Pharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Nasus Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nasus Pharma EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nasus Pharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Nasus Pharma's EV-to-FCF falls into.
Nasus Pharma's current Enterprise Value is $29.91 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nasus Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $-4.92 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nasus Pharma (NSRX) has a EV-to-FCF of -6.08 as of Jul. 22, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Nasus Pharma and its competitors. According to the industry distribution chart, Nasus Pharma ranks #999999 out of 567 companies in the Drug Manufacturers industry.
Is Nasus Pharma's EV-to-FCF too high?
Nasus Pharma's current EV-to-FCF is -6.08. Based on the distribution chart, Nasus Pharma ranks #999999 out of 567 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Nasus Pharma has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Nasus Pharma's EV-to-FCF compare to MIRA and SCLX?
According to the Drug Manufacturers industry distribution chart, Nasus Pharma ranks #999999 out of 567 companies for EV-to-FCF. This places Nasus Pharma in the lower half of its industry. The industry median EV-to-FCF is 21.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.08, based on 567 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Nasus Pharma and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nasus Pharma's current EV-to-FCF is -6.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nasus Pharma stock overvalued right now?
Nasus Pharma (NSRX) has a current EV-to-FCF of -6.08. The current EV-to-FCF is -6.08. Nasus Pharma's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Nasus Pharma (NSRX), the current EV-to-FCF is -6.08 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.
14GF Score
Get the complete analysis for NSRX
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSRX has been successfully added to your 
